Teicoplanin versus cefamandole in the prevention of infection in total hip replacement.

Abstract

In a prospective, controlled, single-blind study the efficacy of teicoplanin versus cefamandole in preventing infections in total hip replacement was investigated in 496 consecutive patients. A single intravenous dose of teicoplanin (400 mg) was as effective as two intravenous doses of cefamandole (2 g before and 1 g after surgery). No major complications were observed in either group. Infective wound complications were observed only in the cefamandole group. These infections, although not dangerous for the patients, required supplementary antibiotic treatment in all cases. Teicoplanin is a reasonable choice as a prophylactic agent in orthopaedic surgery when a high risk of infection due to staphylococci is present.

• Authors: F Suter, A Avai, U Fusco, M Gerundini, S Caprioli, F Maggiolo
• Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 13 Issue 10 Pg. 793-6 (Oct 1994) ISSN: 0934-9723 [Print] Germany
• PMID: 7889947 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Cefamandole
• Teicoplanin

Topics

• Aged
• Cefamandole (administration & dosage, therapeutic use)
• Female
• Hip Prosthesis
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Premedication
• Prospective Studies
• Single-Blind Method
• Surgical Wound Infection (drug therapy, prevention & control)
• Teicoplanin (administration & dosage, therapeutic use)
• Treatment Outcome